Table 4.
Effect of enalapril on all-cause mortality at various time periods in patients with and without chronic kidney disease (CKD), in the SOLVD-Treatment trial
| % (events)
|
Absolute risk difference* (%) | HR (95% CI) | P value | ||
|---|---|---|---|---|---|
| Placebo | Enalapril | ||||
| CKD (n=1036) | n=538 | n=498 | |||
| Duration of follow-up | |||||
| 3 months | 6% (32) | 5% (24) | – 1% | 0.80 (0.47–1.37) | 0.419 |
| 6 months | 12% (64) | 9% (43) | – 3% | 0.71 (0.49–1.05) | 0.088 |
| 12 months | 20% (107) | 15% (73) | – 5% | 0.72 (0.53–0.97) | 0.029 |
| 24 months | 32% (171) | 27% (133) | – 5% | 0.80 (0.64–1.01) | 0.057 |
| 36 months | 40% (217) | 36% (181) | – 4% | 0.86 (0.70–1.05) | 0.127 |
| 48 months | 44% (239) | 41% (202) | – 3% | 0.86 (0.72–1.04) | 0.127 |
| At study end | 45% (242) | 42% (207) | – 3% | 0.88 (0.73–1.06) | 0.164 |
| No CKD (n=1466) | n=714 | n=752 | |||
| Duration of follow-up | |||||
| 3 months | 5% (36) | 3% (24) | – 2% | 0.63 (0.37–1.05) | 0.076 |
| 6 months | 9% (61) | 6% (48) | – 3% | 0.74 (0.50–1.07) | 0.110 |
| 12 months | 13% (90) | 11% (85) | – 2% | 0.88 (0.66–1.19) | 0.401 |
| 24 months | 23% (166) | 19% (139) | – 4% | 0.74 (0.62–0.97) | 0.027 |
| 36 months | 32% (226) | 27% (206) | – 5% | 0.84 (0.69–1.01) | 0.064 |
| 48 months | 36% (257) | 31% (229) | – 5% | 0.82 (0.68–0.97) | 0.024 |
| At study end | 36% (260) | 31% (233) | – 5% | 0.82 (0.69–0.98) | 0.028 |
*
Absolute risk differences were estimated by subtracting event rates in the placebo group from those in the enalapril group